CCL5 and neoplasm: Based on the KM plotter database, the survival rates of patients with high expression of CD73 or CCL5 were significantly decreased in the CD8+ T-cell-rich groups, indicating that CD73 and CCL5 promote tumor progression by inhibiting CD8+ T-cell priming (Supplementary Fig. 16a, b).